newsfilter
← Latest News
Business Wire·

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for